Atrial fibrillation (AF) is a common arrhythmia that is difficult to treat. Anti-arrhythmic drug therapy, to maintain sinus-rhythm, is limited by inadequate efficacy and potentially serious adverse effects. There is increasing interest in novel therapeutic approaches that target AF-substrate development. Recent trials suggest that angiotensin converting-enzyme (ACE)-inhibitors and angiotensin-receptor blockers (ARBs) may be useful, particularly in patients with left ventricular hypertrophy or failure. The clinical potential and mechanisms of this approach are under active investigation. Angiotensin-II is involved in remodelling and may have direct electrophysiological actions. Experimental studies show protection from atrial structural and possibly electrical remodelling with ACE-inhibitors and ARBs, as well as potential effects on cardiac ion-channels. This article reviews information pertaining to the clinical use and mechanism of action of ACE-inhibitors and ARBs in AF. A lack of prospective randomized double-blind trials data limits their application in AF patients without another indication for their use, but studies under way may alter this in the near future. This exciting field of investigation may lead to significant improvements in therapeutic options for AF patients.
Introduction
There is increasing recognition of down-stream effects of the renin-angiotensin-aldosterone system in atrial fibrillation (AF). Angiotensin-II is an octapeptide formed from the liver-derived 485-aminoacid precursor angiotensinogen ( Figure 1 ). Angiotensinogen-gene polymorphisms are associated with increased non-familial AF 1 and angiotensin converting-enzyme (ACE)-inhibitors or angiotensin-receptor blockers (ARBs) may prevent AF in some patients.
Angiotensin-II is important in the regulation of blood pressure, fibroblast proliferation, and cardiac hypertrophy ( Figure 1 ). Angiotensin-II production is enhanced in congestive heart failure (CHF). Beneficial effects of ACE-inhibitors on mortality and morbidity in CHF patients were demonstrated in early clinical trials.
2,3 ACE-inhibition also diminishes ventricular arrhythmias after myocardial infarction (MI). [4] [5] [6] Both ventricular premature contraction numbers and the number of patients affected decline. 6 A retrospective analysis of the SOLVD (Studies of Left Ventricular Dysfunction) trial suggested that ACE-inhibitors prevent AF in overt CHF. 7 Other studies found protective effects of ACE-inhibitors against AF in patients with risk factors like arterial hypertension with left ventricular (LV) hypertrophy 8 or acute MI with reduced left ventricular ejection fraction (LVEF). 9 A recent meta-analysis suggested that renin-angiotensin system inhibition suppresses AF most clearly in patients with LV dysfunction. 10 As previous reviews have summarized clinical evidence of anti-AF efficacy of ACE-inhibitors and ARBs, the present article updates clinical evidence and attempts to elucidate underlying mechanisms.
Methods
A PubMed literature search was performed with the keywords: AF, renin-angiotensin system, ACE-inhibitors, and ARBs. The search was constrained to articles with abstracts in English published between 2000 and 2005. Abstracts were reviewed for appropriateness. Reference lists of identified articles were reviewed for additional papers. Data were extracted from original papers published in peer-reviewed journals.
Clinical evidence ACE-inhibitors reduce the incidence of new-onset AF Table 1 summarizes clinical studies addressing ACE-inhibitor and ARB efficacy in AF.
A retrospective, longitudinal cohort study of 8 million cases compared AF incidence in hypertensive patients treated with ACE-inhibitors vs. calcium-channel blockers. 11 Several trials comparing ACE-inhibitors to other medications (beta-blockers, calcium-channel antagonists, and diuretics) in hypertensive patients found no significant difference. 12, 13 However, the LIFE trial (Losartan Intervention For Endpoint reduction in hypertension) showed significant reductions in AF occurrence for losartan-vs. atenolol-treated patients. 8 ARBs reduced cardiovascular morbidity and mortality and stroke risk in hypertensive patients with previous AF. 8 LIFE studied ARBs in patients with LV hypertrophy, whereas other trials assessed ACE-inhibitors in more general hypertensive populations.
AF is associated with impaired prognosis in post-MI patients.
14 A retrospective study analysed ACE-inhibitor effects on AF occurrence in 1577 patients with sinusrhythm and LVEF ,35% post-MI. 9 ACE-inhibition reduced AF occurrence by 55% vs. placebo (from 5.3 to 2.8%). The reduced AF incidence could not be explained by differences in serum K þ -concentration or LV systolic function, supporting the primary role of ACE-inhibition. 9 In a SOLVD substudy including 391 patients with mean LVEF ,30%, those receiving ACE-inhibitor treatment had reduced new-onset AF during a 2.9 + 1.0-year follow-up (5.4 vs. 24% in placebo). ACE-inhibitors were more beneficial in the prevention arm (with preserved LVEF). 7 Another retrospective analysis of SOLVD evaluated 192 hospitalizations for atrial tachyarrhythmias in 158 patients. 15 ACE-inhibitor treatment was associated with reduced hospitalizations or death [relative risk (RR): 0.87, 95% confidence interval: 0.79-0.96, P , 0.007]. The hospitalization-rate with atrial tachyarrhythmias was also reduced (RR 0.64, 95% confidence interval: 0.48-0.85, P , 0.002). A post hoc analysis of Val-HeFT demonstrated that fewer patients with CHF and sinusrhythm at baseline developed AF when receiving valsartan in addition to ACE-inhibitors (5.12 vs. 7.95%, P , 0.0002). 16 In summary, angiotensin-system inhibition appears to protect against AF in patients with hypertension and LV hypertrophy, post-MI with LV dysfunction, and chronic CHF. The effect is clearest in patients with LV systolic dysfunction Figure 1 Renin-angiotensin system cascade. Angiotensinogen is produced in the liver and split by renin to form angiotensin-I. ACE transforms angiotensin-I into physiologically active angiotensin-II. Two types of angiotensin-receptors mediate different physiological responses. Angiotensin-II production by chymases also contributes. A local renin-angiotensin system is present in many organs. BP, blood pressure; ADH, anti-diuretic hormone; RAS, renin-angiotensin system; AngII, angiotensin-II. and CHF. 10 As AF incidence was not a pre-specified endpoint in these retrospective studies, results need to be confirmed in prospective clinical trials. In addition, renin-angiotensin system inhibition effects on AF occurrence in patients without another medical indication for angiotensin-inhibitor treatment like hypertension, post-MI LV dysfunction or CHF, have not been systematically tested. The ongoing ACTIVE trial has a study arm comparing irbesartan vs. placebo. 17 Another ongoing trial is studying olmesartan in paroxysmal AF (ANTIPAF: Angiotensin-II Receptor Blocker in Paroxysmal Atrial Fibrillation Trial).
ACE-inhibitors prevent AF relapse after electrical cardioversion
ACE-inhibition produced favourable haemodynamic effects and improved peak oxygen-consumption in CHF associated with AF, 18 with a trend towards better sinus-rhythm maintenance (71%) vs. placebo (36%, P ¼ n.s.) post-cardioversion. Retrospective analysis of 732 patients randomized to rhythm-control within AFFIRM demonstrated fewer AF relapses in ACE-inhibitor treated patients with CHF. 19 Madrid et al. 20 prospectively studied the effects of adding irbesartan to amiodarone-treatment after electrical cardioversion. AF recurrences were reduced in irbesartan-receiving patients. Similarly, Ueng et al. 21 showed that adding an ACE-inhibitor to amiodarone reduced AF relapses postcardioversion. In these trials, a combination of renin-angiotensin system inhibition with efficient anti-arrhythmic therapy led to further improved outcome in terms of freedom from arrhythmia relapse, albeit over a relatively short time-frame. A third trial demonstrated abbreviated signal-averaged P-wave duration, reflecting improved atrial conduction, after cardioversion in patients on longterm (6-12 months) ACE-inhibitor treatment. 
ACE-inhibitors reduce atrial stretch
Haemodynamic effects of ACE-inhibitors include systemicarteriolar dilatation and increased large-artery compliance that decrease systolic blood pressure. In CHF, renin-angiotensin system inhibition reduces afterload and systolic wall-stress, improving cardiac function. 23 ACE-inhibition also decreases left-atrial pressure and wall-stress. 24 Acutely raised pressure increases atrial vulnerability by shortening refractory periods, 25 possibly by opening stretch-activated channels. 26 Atrial stretch following mitral-valve chordae tendineae rupture changes atrial electrophysiology (pronounced conduction slowing of premature beats), similar to experimental CHF-related AF. 27, 28 Experimental CHF includes a significant stretch component, as most CHF animals develop mitral regurgitation. 28 Mitral regurgitation slows impulse propagation, promoting AF in dogs. 29 Sheep subjected to aorto-pulmonary shunt-generation develop left-atrial dilatation and altered atrial electrophysiology (action-potential shortening; I Ca,Lreduction), along with predisposition to AF. 30 Rabbits with chronic volume overload demonstrate re-entrant and focal left-atrial activity. 31 Stretch is not the only determinant of the AF substrate in CHF. AF can still be induced despite reversal of atrial dilatation after recovery from tachypacing-induced CHF. 32 Mimicking the haemodynamic effects of ACE-inhibition does not suppress experimental CHF-related AF, whereas ACE-inhibition does, suggesting that haemodynamic effects are insufficient to account for ACE-inhibitor actions. 33 
Preventing fibrosis
Angiotensin-II regulates cardiac-fibroblast proliferation. 34 Transforming growth factor-b1 (TGF-b1) may be particularly important for atrial fibrosis. [35] [36] [37] Angiotensin-II binding to AT 1 receptors stimulates fibrous-tissue formation by promoting TGF-b1 synthesis. 35 Selective cardiac overexpression of TGF-b1 in transgenic mice causes atrial but not ventricular fibrosis, with predisposition to AF. 36 There are greater local angiotensin-II levels in atria than ventricles of CHF dogs and atrial (but not ventricular) TGF-b1 is activated during the development of CHF. 37 Cardiac-specific ACE overexpression produces atrial enlargement and AF, 38 consistent with an angiotensin-II/fibrosis/AF link.
In experimental CHF, ACE-inhibitor treatment inhibits fibrosis and reduces AF duration. 33 CHF-induced ioncurrent changes are reversible upon recovery from experimental CHF but atrial fibrosis persists, along with increased AF duration. 32 However, ACE-inhibitor protection against fibrosis and AF promotion is incomplete, and some changes (cell death, inflammatory-cell infiltration, activation of mediators) are not prevented. 39 Increased atrial angiotensin-II concentrations precede plasma concentration rises in ventricular-tachypacing induced CHF, 39 suggesting intracardiac angiotensin-II formation. Local ACE-synthesis is increased in chronic human AF. 40 In human right-atrial samples, AT 1 -and AT 2 -receptors may be differentially regulated in AF: AT 1 -receptors downregulated and AT 2 -receptors (with potential anti-proliferative actions) upregulated. 41 In other studies, AT 1 -receptors were found to be upregulated in left and unchanged in right atria 42 and experimental data demonstrated increased AT 1 -and AT 2 -receptor expression. 33 Thus, angiotensin-receptor behaviour in AF remains unclear. AT 1 -receptor agonist-binding triggers phosphatidylinositol-signalling, activating mitogen activated protein-kinases that initiate hypertrophy. 40, 43 ARBs can modulate cardiac angiotensin-II effects by blocking AT 1 -receptors in the presence of unhindered stimulation of AT 2 -receptors; however, there is no evidence to suggest superiority of ARBs vs. ACE-inhibitors in AF.
There is evidence for a role of angiotensin-II in mediating inflammatory responses, which may additionally be involved in AF. 44 Aldosterone-antagonism reduces ventricular fibrosis in hypertensive heart disease and might be useful in preventing atrial fibrosis. 45 
Anti-arrhythmic effects of ACE-inhibitors and ARBs
ACE-inhibitors and ARBs prevented atrial electrophysiological changes during several hours of atrial tachycardia in dogs. 46 However, although angiotensin-II infusion to patients increased blood pressure, there was no change in atrial ERP, ERP-dispersion, conduction properties, or AF inducibility. 47 Enalapril does not affect atrial remodelling caused by 7-day atrial-tachypacing. 48 Sustained AF induced in dogs by 5-week atrial-tachypacing, with uncontrolled ventricular rates, caused LV-dysfunction. Candesartan (10 mg/kg/day), started a week before tachypacing-onset and continued throughout tachypacing, reduced AF duration. 49 Atrial ERP-shortening was unaffected, indicating benefit independent of rate-dependent remodelling. 49 Candesartan reduced interstitial fibrosis (7+2 vs. 16 + 1% in controls, P , 0.001), suggesting that efficacy against AF was because of prevention of tachycardiomyopathy-induced structural remodelling. 33 
Effects on cellular electrophysiology
Direct cellular electrophysiological effects of angiotensin-II are controversial. L-and T-type Ca 2þ -current (I Ca,L , I Ca,T ) regulation by angiotensin-II has been reported. 50 ,51 Intracellular angiotensin-II reduced I Ca,L in rat ventricular cells, whereas the opposite was observed in hamsters. 50 Angiotensin-II increases I Ca,L through PKC-dependent pathways. 52 I Ca,T is increased by angiotensin-II stimulation. 51 As I Ca,T blockade prevents AF-substrate development, 53 renin-angiotensin system inhibition might be beneficial by preventing angiotensin-II-mediated I Ca,T increases. However, the lack of ACEinhibitor benefit against 1-week atrial-tachycardia remodelling, 48 in contrast to the clear benefit from the I Ca,T -inhibitor mibefradil in the same model, 53 argues against an I Ca,Tinhibition mediated mechanism for ACE-inhibitor benefit.
Modulation of K þ -currents has also been reported. The rapid delayed-rectifier current (I Kr ) in guinea pig ventricular myocytes is increased by clinically relevant concentrations of angiotensin-II (30 nmol/L), whereas the slow component (I Ks ) is decreased. 54 Transcriptional I to -downregulation is a hallmark of AF-induced electrical remodelling. The AT 1 -receptor forms a complex with Kv4.3 (the poreforming ion-channel a-subunit underlying the transient outward potassium current, (I to ) and regulates its cellsurface expression. 56 Stimulation of the receptor with angiotensin-II leads to internalization of the complex, which could contribute to I to -reduction. Ventricular action potential duration (APD) is prolonged by angiotensin-II, and ACE-inhibitors reverse these changes while promoting cellto-cell communication. 57 In vitro studies with heterologously expressed K þ -channel subunits show varying effects of ARBs. Losartan blocks currents carried by HERG (corresponding to I Kr ), KvLQT1 and minK (I Ks ) and hKv1.5 subunits (ultrarapid delayed-rectifier current, I Kur ). 58 The drug prolongs guinea pig ventricular APD, whereas its metabolite E-3174 reduces APD. 58 Candesartan, eprosartan, and irbesartan inhibit currents carried by hKv1.5, HERG, KvLQT1 þ mink, and rKv4.3 subunits. 59 While irbesartan blocks rKv4.3 and hKv1.5 at therapeutic concentrations, blockade of HERG and KvLQT1 þ minK currents occurs only at supra-therapeutic levels ( Table 2) .
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+ 50 mmol/L) # (IC 50 ¼ 315 + 85 mmol/L) # (max. tail-current block ¼ 27 + 1%; IC 50 ¼ 0.7 + 0.2 mmol/L) # (max. block ¼ 46 + 6%, C 50 ¼ 1.0 + 0.4 mmol/L)
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Overall, these observations suggest that the renin-angiotensin system could affect ion-channels, APD and impulse propagation, and facilitate re-entry. On the other hand, there is no measurable effect of acute angiotensin-II on human atrial electrophysiology. 47 ARBs may also be beneficial in acute atrial remodelling by directly inhibiting repolarizing K þ -currents. Some ARBs inhibit Kv1.5-currents, which underlie the atrially expressed I Kur , 62, 63 an emerging target for AF therapy. 64 
Conclusions
Both ACE-inhibitors and ARBs appear to reduce AF incidence and may prevent AF-related complications. However, there are insufficient prospective double-blinded trial data and there is thus no solid clinical evidence to recommend ACEinhibitor or ARB treatment solely for AF prevention at this time. Presently, ongoing clinical trials will help to understand the value of these drugs in AF management. Some issues remain to be studied on the basic science level. Clinical evidence demonstrates beneficial effects of ACE-inhibitor treatment in patients with risk factors for AF (e.g. heart failure, hypertension with LV hypertrophy). There is lack of experimental data addressing the effects of renin-angiotensin system inhibition applied after the development of such substrates. Furthermore, the effect of combining ARB and ACEinhibitor treatment has not been studied.
The clinical anti-arrhythmic actions of ACE-inhibitors and ARBs may be mediated by prevention of structural remodelling. Direct ion-channel modulating properties might also contribute. Further studies of atrial remodelling changes and direct electrophysiological consequences of ACE-inhibitor and ARB therapy in human would be useful in elucidating clinically relevant mechanisms of action.
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